BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...expected to begin this year.A CRISPR/Cas9-based histone kinaseAn article in Nature Communications described a programmable chromatin...
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...San Francisco Bay Area office.Michael LaCascia joined chromatin...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...HMGB1, a DNA binding protein that regulates chromatin...
...HMGB1 protected SARS-CoV-2-induced cell death and diminished chromatin...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...these epigenetic targets. You can start with chromatin...
BioCentury | Oct 24, 2020
Finance

Data Byte: new entrants to IPO queue as NASDAQ tops $16B raised from biotechs

...shares at $16, the midpoint of its proposed range. The company is designing small molecules that regulate chromatin...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...Therapeutics Inc. filed for a NASDAQ listing. The company is designing small molecules that regulate chromatin...
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...Founded by Flagship Pioneering in 2017, Omega has raised $85 million to develop therapies targeting chromatin...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...$85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

...work includes dynamic modeling, virtual screening and medicinal chemistry studies to identify compounds that reduce chromatin...
BioCentury | Jul 8, 2020
Deals

Chromatin remodeling gains traction with Merck-Foghorn partnership

...Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under...
...cancer therapies targeting dysregulation of an undisclosed transcription factor that emerge from Foghorn Therapeutics Inc.’s chromatin...
...focused on chromatin biology: Omega Therapeutics Inc. Rather than developing compounds targeting proteins involved with chromatin...
Items per page:
1 - 10 of 239
BioCentury | Feb 19, 2021
Translation in Brief

mAb reduces amyloid plaques without hemorrhage; plus Dyno and Ally’s AAV technologies and more

...expected to begin this year.A CRISPR/Cas9-based histone kinaseAn article in Nature Communications described a programmable chromatin...
BioCentury | Nov 14, 2020
Management Tracks

Legend’s new look at the top; plus VC moves at Medicxi, OSI and Qiming

...San Francisco Bay Area office.Michael LaCascia joined chromatin...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...HMGB1, a DNA binding protein that regulates chromatin...
...HMGB1 protected SARS-CoV-2-induced cell death and diminished chromatin...
BioCentury | Oct 30, 2020
Product Development

José Baselga on how new modalities and biomarkers are shaping AZ’s oncology strategy

...these epigenetic targets. You can start with chromatin...
BioCentury | Oct 24, 2020
Finance

Data Byte: new entrants to IPO queue as NASDAQ tops $16B raised from biotechs

...shares at $16, the midpoint of its proposed range. The company is designing small molecules that regulate chromatin...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...Therapeutics Inc. filed for a NASDAQ listing. The company is designing small molecules that regulate chromatin...
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...Founded by Flagship Pioneering in 2017, Omega has raised $85 million to develop therapies targeting chromatin...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

...$85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

...work includes dynamic modeling, virtual screening and medicinal chemistry studies to identify compounds that reduce chromatin...
BioCentury | Jul 8, 2020
Deals

Chromatin remodeling gains traction with Merck-Foghorn partnership

...Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under...
...cancer therapies targeting dysregulation of an undisclosed transcription factor that emerge from Foghorn Therapeutics Inc.’s chromatin...
...focused on chromatin biology: Omega Therapeutics Inc. Rather than developing compounds targeting proteins involved with chromatin...
Items per page:
1 - 10 of 239